Review of Treatment of Vasculogenic Erectile Dysfunction with Piezowave2 Device—Motil 2016

This is a brief audio review. In the article Treatment of Vasculogenic Erectile Dysfunction with Piezowave2 Device. Application of Low Intensity Shockwaves Using Novel Linear Shockwave Tissue Coverage (LSTC-ED®) Technique. A Prospective, Multicentric, Placebo-Controlled Study published, 2016 by Motil and Colleagues, The outcomes and key points are as noted: Low intensity Shockwave improves revascularization. The approach treats vasculogenic erectile dysfunction (ED). The current study aims to demonstrate the efficacy of a linear focused piezoelectric shockwave device from Richard Wolf called ELvationPiezowave2 to treat vasculogenic Erectile Dysfunction using a novel linear shockwave tissue coverage "L-S-T-C-E-D" technique. Piezowave2 and L-S-T-C-E-D® were used to treat 75 patients. At the commencement of treatment and 1 month after treatment, patients' erectile function was measured using the modified International Index of Erectile Function-version 5 scale. Patients were also asked to complete our Treatment Satisfaction Questionnaire. The results of 50 placebo-treated patients were also compared. The International Index of Erectile Function-version 5 score of treatment group patients rose from 14.4 to 18.6 after 1 month. Treatment was successful in 81.33 percent of patients (61 out of 75 patients), according to the International Index of Erectile Function-version 5. According to the Treatment Satisfaction Questionnaire (answers 1 to 3), 77.3% of patients (58 out of 75 patients) were treated successfully. In the placebo group of 50 patients, only 5 exhibited an improvement on the International Index of Erectile Function scale and 8 on the Treatment Satisfaction Questionnaire. Neither therapy nor follow-up revealed any substantial side effects. Piezowave2 and L-S-T-C-E-D® are effective erectile dysfunction treatments.This was a Prospective Randomized Controlled Trial (Multicenter) with 125 patients who were Heterosexual men between the ages of 36 and 71 years old, with with vasculogenic erectile dysfunction for at least 6 months, an International Index of Erectile Function score between 7 and 21 while on a Phosphodiesterase-5 inhibitor drug, and in a stable heterosexual relationship since at least 6 months.